El dapirotuzumab (pegilado) ha demostrado tener potencial para reducir la tasa de recaídas del lupus eritematoso sistémico (LES) y mantener el control de la enfermedad.
Bruselas, Bélgica y Cambridge, Massachusetts, EE.
该文章暂未提取到完整正文，已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。
Preguntas frecuentes
Which products are related to this article?
No strongly related product has been identified yet. The match updates automatically when the article or catalog changes.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.
